The development of head and neck cancer is a multistep process in which genetic as well as epigenetic alterations interfere with the regular functions of proto-oncogenes and tumor suppressor genes. In addition, carcinogenesis is promoted by the impairment of mechanisms responsible for the maintenance of genetic stability. The accumulation of crucial events such as evasion of apoptosis, lack of senescence, deregulated proliferation, invasion and metastasis, as well as neoangiogenesis eventually determines the malignant phenotype. The 16 articles of this volume span from advances in the understanding of underlying molecular pathways (conditional mouse model, folate activity, DNA repair, genomic heterogeneity, p53 family members, human papillomavirus), to preclinical and clinical studies investigating potential novel therapeutic targets (epidermal growth factor receptor, nuclear factor-kappaB, vascular endothelial growth factor, chemokine receptors, P53-based immunotherapy, virus-modified tumor vaccination), and biometric considerations on the evaluation of prognostic factors. This state-of-the-art publication is recommended reading not only for ENT specialists and oncologists, but also for molecular biologists and other subspecialists interested in head and neck cancer research.

Novel Therapies in Head and Neck Cancer: Beyond the Horizon, Volume Twelve, provides a high-level synthesis of the latest treatments and outcomes relating to head and neck cancer. Chemotherapy and immunotherapy for those cancer types are rapidly evolving, and an updated source based on the expertise of internationally renowned researchers is necessary. This book discusses the outcome of recent trials using chemotherapy, novel approaches for HPV+ SCCA, cases in which immunotherapy is more likely to be successful, and precision medicine based on target therapies. Additionally, new approaches for rare diseases in head and neck and novel drug delivery platforms are presented. This book will be a very useful source so that students, scientists and clinicians who can be facile with the data, build on what is known, and continue to offer cutting-edge, validated therapies to all patients.

Imaging is crucial in the multidisciplinary approach to head and neck cancer management. The rapid technological development of recent years makes it necessary for all members of the multidisciplinary team to understand the potential applications, limitations, and advantages of existing and evolving imaging technologies. It is equally important that the radiologist has sufficient clinical background knowledge to understand the clinical significance of imaging findings. This book provides an overview of the findings obtained using different imaging techniques during the evaluation of head and neck neoplasms, both before and after therapy. All anatomic areas in the head and neck are covered, and the impact of imaging on patient management is discussed in detail. The authors are recognized experts in the field, and numerous high-quality images are included. This second edition provides information on the latest imaging developments in this area, including the application of PET-CT and diffusion-weighted magnetic resonance imaging.

The purpose of this book is to provide a current perspective on the epidemiology head and neck cancer. Cancers of the oral cavity, pharynx, and larynx comprise an important group of tumors with diverse international patterns of incidence and mortality, established risk factors, suggested association with a virus, and potential genetic susceptibility determinants. These tumors offer a unique insight into mechanisms of cancer initiation and progression and gene-exposure interaction.

​This second edition ​provides a comprehensive view of consolidated and innovative concepts, in terms of both diagnosis and treatment. Written by leading international physicians and investigators, this book emphasizes the necessity of combining local and systemic treatments to achieve the objective of yielding higher cure rates and lower toxicities. Heavily updated from the previous edition, it highlights new surgery and radiotherapy techniques, disease awareness, patient quality of life, and comprehensive management. Head-and-neck cancers are a complex clinical entity and their response to treatment is also known to vary markedly in function of host-related factors. Notwithstanding the impressive progresses observed in the field of imaging, head and neck cancers are often diagnosed at a late stage and the presence of locally advanced disease in a significant number of patients implies the use of aggressive treatments in order to both ensure local disease control and reduce distant metastasis risks. In comparison with the first edition, Head and Neck Cancer, Second Edition provides a detailed update of innovative concepts in chemo- and bio-radiation, viral infection impact on tumor growth and response to treatment, and impact of tumor- and host-related factors on treatment outcome.

Tumor biology varies at different subsites in the oral cavity, and therefore carcinoma of the gingivo-buccal sulcus (also known as Indian cancer) behaves differently from carcinoma of the tongue. Oral cancer is very often diagnosed at an advanced stage with neck metastasis, and most cases have a guarded prognosis. Loco-regional recurrences are frequent and morbidity following treatment is considerable. However, results have improved in recent years, particularly in early and certain advanced stages, due to better imaging and case selection, improved surgical techniques, including those for reconstructive surgery, a multidisciplinary team approach and a better understanding of tumor biology and prognostic factors. This book comprehensively and systematically reviews all these aspects of diagnostic and therapeutic advances in oral cancer, particularly discussing early detection, epidemiology, chemoprevention and current research. Written by specialists who are active leaders in basic sciences or clinical fields, the chapters address individual and collective issues in managing patients with oral cancer, and provide insights into various treatment approaches. The authors share their knowledge and experience and provide extensive literature sources to encourage clinicians to be flexible, innovative and help them make the best, educated decisions for individual patients.

A working group of sixteen experts from seven countries re-evaluated the evidence of the carcinogenicity of betel-quid and areca-nut chewing and some areca-nut related nitrosamines. Betel-quid and areca-nut chewing are widely practised in many parts of Asia and in Asian-migrant communities elsewhere in the world. There are hundreds of millions of users worldwide. They evaluated betel quid with tobacco as carcinogenic to humans (Group 1) on the basis of sufficient evidence of an increased risk of cancer of the oral cavity, pharynx and oesophagus. The working group reviewed epidemiological studies of human cancer, mainly studies from India, Pakistan and Taiwan (China). Studies on betel quid with tobacco and areca nut with tobacco in experimental animals now also provide sufficient evidence of carcinogenicity. The working group also evaluated betel quid without tobacco as carcinogenic to humans (Group 1), on the basis of sufficient evidence of an increased risk of oral cancer. Studies on betel quid without tobacco and areca nut without tobacco in experimental animals now also provide sufficient evidence of carcinogenicity. Areca nut, a common ingredient of betel quid and many different chewing preparations, including those available commercially, has been observed to cause oral submucous fibrosis